InsiderSignal.AI

InsiderSignal.ai

TNGX - Tango Therapeutics, Inc.

Insider Sale by Crystal Adam (Pres, R, D)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Crystal Adam, serving as Pres, R, D at Tango Therapeutics, Inc. (TNGX), sold 38,460 shares at $25.00 per share, for a total transaction value of $961,500.00. Following this transaction, Crystal Adam now holds 112,622 shares of TNGX.

This sale represents a 25.00% decrease in Crystal Adam's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, April 15, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 16, 2026, 1 day after the trade was made.

Tango Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Crystal Adam

Crystal Adam

Pres, R, D

Crystal Adam is the President of Research & Development (R&D) at Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company founded in 2017 focused on discovering and developing novel precision medicines for cancer.[[1]](https://www.biocentury.com/article/647000/c4-s-adam-crystal-to-head-r-d-at-tango)[[5]](https://www.zoominfo.com/p/Adam-Crystal/9195419130) She joined Tango in March 2023, following her role as Chief Medical Officer (CMO) at C4 Therapeutics Inc. (NASDAQ: CCCC), and prior positions in the oncology division at Novartis Institutes for BioMedical Research.[[1]](https://www.biocentury.com/article/647000/c4-s-adam-crystal-to-head-r-d-at-tango) As President, R&D, Adam oversees Tango's clinical programs, including the ongoing dose escalation study of its first trial and plans to advance additional programs.[[1]](https://www.biocentury.com/article/647000/c4-s-adam-crystal-to-head-r-d-at-tango) She has recently engaged in insider trading activities, exercising stock options and selling shares under a Rule 10b5-1 plan, including 12,000 shares on March 25, 2026, at $20.11 average price, and 27,000 shares on April 1, 2026, for approximately $572,000.[[2]](https://www.stocktitan.net/sec-filings/TNGX/form-4-tango-therapeutics-inc-insider-trading-activity-d7ba2689df4d.html)[[3]](https://www.webull.ca/news-detail/14611209460188160)[[6]](https://www.investing.com/news/insider-trading-news/tango-therapeutics-president-sells-572k-in-shares-93CH-4596726)

View full insider profile →

Trade Price

$25.00

Quantity

38,460

Total Value

$961,500.00

Shares Owned

112,622

Trade Date

Wednesday, April 15, 2026

2 days ago

SEC Filing Date

Thursday, April 16, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Tango Therapeutics, Inc.

Company Overview

No company information available
View news mentioning TNGX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5698543

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime